These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22307951)

  • 1. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
    ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
    Zindo FT; Barber QR; Joubert J; Bergh JJ; Petzer JP; Malan SF
    Eur J Med Chem; 2014 Jun; 80():122-34. PubMed ID: 24769350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors.
    Prins LH; Petzer JP; Malan SF
    Bioorg Med Chem; 2009 Nov; 17(21):7523-30. PubMed ID: 19804982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
    Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ
    J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent polycyclic ligands for nitric oxide synthase (NOS) inhibition.
    Joubert J; van Dyk S; Malan SF
    Bioorg Med Chem; 2008 Oct; 16(19):8952-8. PubMed ID: 18805011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
    Joubert J; van Dyk S; Green IR; Malan SF
    Bioorg Med Chem; 2011 Jul; 19(13):3935-44. PubMed ID: 21665485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorinated molecules in the diagnosis and treatment of neurodegenerative diseases.
    Gaye B; Adejare A
    Future Med Chem; 2009 Aug; 1(5):821-33. PubMed ID: 21426082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
    Geldenhuys WJ; Malan SF; Bloomquist JR; Van der Schyf CJ
    Bioorg Med Chem; 2007 Feb; 15(3):1525-32. PubMed ID: 17157509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cholinergic system, sigma-1 receptors and cognition.
    van Waarde A; Ramakrishnan NK; Rybczynska AA; Elsinga PH; Ishiwata K; Nijholt IM; Luiten PG; Dierckx RA
    Behav Brain Res; 2011 Aug; 221(2):543-54. PubMed ID: 20060423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally designed multi-targeted agents against neurodegenerative diseases.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Med Chem; 2013; 20(13):1662-72. PubMed ID: 23410161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives.
    Geldenhuys WJ; Malan SF; Bloomquist JR; Marchand AP; Van der Schyf CJ
    Med Res Rev; 2005 Jan; 25(1):21-48. PubMed ID: 15389731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
    Van der Schyf CJ; Gal S; Geldenhuys WJ; Youdim MB
    Expert Opin Investig Drugs; 2006 Aug; 15(8):873-86. PubMed ID: 16859391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB; Buccafusco JJ
    Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.